Last reviewed · How we verify

NCT04065321

Circulating Tumor Cell Detection in Patients With Luminal A Breast Cancer

Recruiting now Last updated 5 May 2022
What this trial tests

trial testing PET-CT examination in Breast Neoplasms in 500 participants. Currently enrolling.

Timeline
1 October 2019
Primary endpoint
30 September 2024
30 September 2029

Quick facts

Lead sponsorShengjing Hospital
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment500
Start date1 October 2019
Primary completion30 September 2024
Estimated completion30 September 2029
Sites2 locations across China

Drugs / interventions tested

Conditions studied

Sponsor

Shengjing Hospital

Who can join

Adults 18 to 60, female only, with Breast Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The incidence of breast cancer in Chinese women has increased year by year, and luminal A breast cancer commonly occurs in early-stage and postmenopausal women. This type of breast cancer is not sensitive to chemotherapy, although it has a low mortality rate and distant metastasis rate. Studies have shown that luminal A breast cancer is sensitive to endocrine therapy. Patients with breast cancer who undergo excision should be followed up and their prognosis should be monitored regularly. At present, imaging detection is mainly used in the conventional follow-up of breast cancer, but the cost of many imaging examinations is high, so a cost-effective examination is urgently needed. Recent studies have found that circulating tumor cells can be used as a new type of tumor molecular marker, which can be used to diagnose tumors, judge the prognosis and monitor the efficacy by detecting the number and characteristic protein expression of circulating tumor cells. Because circulating tumor cells may develop abnormalities 4-6 months earlier than conventional imaging examination, as long as circulating tumor cells of patients are abnormal, timely PET-CT examination will neither miss diagnosis nor delay the condition. Simultaneously, the cost of hospitalization can be obviously reduced. This non-inferiority randomized controlled clinical trial is designed to compare the differences in postoperative conditions between circulating tumor cell detection and conventional imaging examination in patients with luminal A breast cancer without lymph node metastasis.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Redefining cancer care: harnessing circulating tumor cells' potential for improved diagnosis and prognosis.
    Janjua D, Chaudhary A, Joshi U, Tripathi T, et al · · 2025 · cited 4× · PMID 40676582 · DOI 10.1186/s12935-025-03883-y
  2. Liquid biopsy in breast cancer: Redefining precision medicine.
    Schiavone ML, Scarpitta R, Ravera F, Bleve S, et al · · 2025 · cited 3× · PMID 40740670 · DOI 10.1016/j.jlb.2025.100312
  3. Detection, significance and potential utility of circulating tumor cells in clinical practice in breast cancer (Review).
    Rusnáková DŠ, Aziri R, Dubovan P, Jurík M, et al · · 2025 · cited 3× · PMID 39492933 · DOI 10.3892/ol.2024.14756
  4. Circulating Tumor Cell Detection for Therapeutic and Prognostic Roles in Breast Cancer.
    Ma S, Wang X, Lin PP, Lei L. · · 2025 · cited 1× · PMID 40437761 · DOI 10.1002/cam4.70902

Verify or expand the search:

Other trials of PET-CT examination

Trials testing the same drug.

Other recruiting trials for Breast Neoplasms

Currently open trials in the same condition.

Other Shengjing Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04065321.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing